A mother’s perspective on Sarepta’s gene therapy halt

Will Sarepta's Elevidys ever come back to the market?

July 25, 2025 Check out STAT+

Sponsored By

How are families of patients reacting to the removal of Sarepta's gene therapy from the market? Why are investors excited about narcolpesy drugs? And why has there been less financing in oncology startups? We chat about all that and more on this on this week's episode of "The Readout LOUD," STAT's biotech podcast. We bring on a mother whose 7-year-old has Duchenne muscular dystrophy, and hear her thoughts on Sarepta's decision to pull its treatment Elevidys from the market, following a request from the Food and Drug Administration. Listen Now Subscribe to the podcast on Apple Podcasts or Spotify to never miss an episode Visit the archive to see past episodes

---

---

Enjoying The Readout LOUD? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser